Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurocrine Biosciences Inc (Nasdaq: NBIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, publicly traded biopharmaceutical company, Neurocrine Biosciences reports its financial performance, material events and key corporate developments through forms such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports.
In its recent Form 8-K filings, Neurocrine Biosciences has reported quarterly financial results, including net product sales for INGREZZA and CRENESSITY, research and development and selling, general and administrative expenses, and net income. These filings often incorporate press releases that discuss revenue trends, non-GAAP financial measures, R&D investment in programs such as osavampator and direclidine, and updates on collaborations. Other 8-K items may cover executive and board-related matters, such as amendments to employment agreements and changes in key leadership roles.
On this page, investors can review the full text of Neurocrine Biosciences’ periodic reports to understand how the company describes its business, risk factors, product portfolio and pipeline. The annual Form 10-K typically includes detailed sections on therapeutic focus areas like tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as discussion of the company’s neuroscience and endocrinology research strategy. Quarterly Form 10-Q filings update these disclosures and provide interim financial statements.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, helping readers quickly identify changes in revenue composition, R&D spending, collaboration milestones and other material items. Users can also monitor real-time 8-K updates for new clinical data announcements, financing activities or governance changes, and access Form 4 insider transaction reports to see how company insiders are trading NBIX shares, when such filings are available.
Whether you are evaluating Neurocrine Biosciences’ exposure to specific therapeutic areas, following its investment in late-stage programs like osavampator and direclidine, or comparing GAAP and non-GAAP results, this filings page offers a structured view of the company’s official SEC record with tools that make complex disclosures easier to interpret.
Neurocrine Biosciences (NBIX) ownership update: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating it reports beneficial ownership of 0 shares of Neurocrine Biosciences common stock, representing 0%. The filing explains that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report holdings separately on a disaggregated basis in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and affirms Vanguard (including related investment companies and managed accounts) has rights to receive dividends or sale proceeds for reported securities where applicable.
Neurocrine Biosciences executive Andrew Ratz has reported his initial equity holdings as Chief Technical Operations Officer. The Form 3 shows direct ownership of 1,018 shares of common stock and several equity awards that may convert into additional shares over time.
He holds restricted stock units tied to 3,997 and 5,640 underlying shares of common stock, which vest in annual installments through February 2029 and February 2030. He also holds incentive and non-qualified stock options covering 2,664 and 17,724 shares at an exercise price of $150.10 expiring in 2035, and 805 and 31,348 shares at $124.12 expiring in 2036, subject to monthly vesting schedules. These awards represent potential future ownership if vesting and exercise conditions are met.
Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported a charitable stock gift. On March 4, 2026, he transferred 2,249 shares of Neurocrine Biosciences common stock as a bona fide gift, with no value received and no market transaction involved.
After this disposition, he directly holds 42,808 shares of common stock, which include 176 shares purchased on February 27, 2026 under the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences Chief Scientific Officer makes charitable stock gift
Neurocrine Biosciences’ Chief Scientific Officer, Jude Onyia, reported a bona fide gift of 3,110 shares of common stock effective February 20, 2026. The filing states this was a gift/charitable contribution, not a market transaction, so no price or proceeds were involved. After the transfer, Onyia directly holds 25,670 shares of Neurocrine Biosciences common stock.
ABERNETHY MATT reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 84,802 shares at a weighted average price of $123.99 per share. Following the reported transactions, holdings were 4,484 shares.
Boyer David W. reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 64,637 shares at a weighted average price of $124.01 per share. Following the reported transactions, holdings were 3,083 shares.
Gano Kyle reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 174,989 shares at a weighted average price of $123.87 per share. Following the reported transactions, holdings were 4,484 shares.
Onyia Jude reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 115,756 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 5,380 shares.
BENEVICH ERIC reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 83,590 shares at a weighted average price of $124.03 per share. Following the reported transactions, holdings were 3,924 shares.
Cooke Julie reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 58,116 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 2,802 shares.